Philip Marks
Health Protection Agency
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Philip Marks.
Biochemical and Biophysical Research Communications | 2009
Geoffrey Masuyer; Nethaji Thiyagarajan; Peter James; Philip Marks; John Chaddock; K. Ravi Acharya
Botulinum neurotoxins (BoNTs) modulate cholinergic nerve terminals to result in neurotransmitter blockade. BoNTs consists of catalytic (LC), translocation (Hn) and cell-binding domains (Hc). The binding function of the Hc domain is essential for BoNTs to bind the neuronal cell membrane, therefore, removal of the Hc domain results in a product that retains the endopeptidase activity of the LC but is non-toxic. Thus, a molecule consisting of LC and Hn domains of BoNTs, termed LHn, is a suitable molecule for engineering novel therapeutics. The structure of LHA at 2.6 A reported here provides an understanding of the structural implications and challenges of engineering therapeutic molecules that combine functional properties of LHn of BoNTs with specific ligand partners to target different cell types.
Protein Expression and Purification | 2005
J. Mark Sutton; Jonathan Wayne; Anthony Scott-Tucker; Susan O‘Brien; Philip Marks; Frances Alexander; Clifford C. Shone; John Chaddock
Military Medicine | 1976
Keith Foster; John Chaddock; Philip Marks; Patrick Stancombe; K. Roger Aoki; Joseph Francis; Lance E. Steward
Archive | 2005
Keith Foster; John Chaddock; Philip Marks; Patrick Stancombe; Lyndsey Durose
Archive | 2007
Keith Foster; John Chaddock; Philip Marks; Patrick Stancombe; K. Roger Aoki; Joseph Francis; Lance E. Steward
Archive | 2009
Frederic Madec; Phil Lecane; Philip Marks; Keith Foster
Archive | 2009
Stephen Johnstone; Philip Marks; Keith Foster
Archive | 2009
Frederic Madec; Philip Lecane; Philip Marks; Keith Foster
Archive | 2009
Frederic Madec; Philip Lecane; Philip Marks; Keith Foster
Archive | 2009
Frederic Madec; Philip Lecane; Philip Marks; Keith Foster